IBM and Illumina Partner to Standardize Genomic Data Interpretation
IBM Watson Health and Illumina, Inc. announced a partnership to integrate Watson for Genomics into Illumina’s BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation and will begin in early 2017.
By adding Watson for Genomics to Illumina’s next-generation sequencing platform, researchers will have rapid access to information to help interpret the broad array of variant data produced by TruSight Tumor 170, Illumina’s solid tumor profiling panel. In a matter of minutes, Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170, comb professional sources to provide information for each genomic alteration, and produce a report — a process that typically takes scientists over a week to complete.
